Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu
Roche (Nutley, NJ) has introduced a flexible purchase program that will allow US businesses to maintain access to their own stockpile of Tamiflu for use in a pandemic situation, with limited upfront investment and more adaptability to deal with unknown factors inherent in pandemic planning.
Roche (Nutley, NJ) has introduced a flexible purchase program that will allow US businesses to maintain access to their own stockpile of Tamiflu for use in a pandemic situation, with limited upfront investment and more adaptability to deal with unknown factors inherent in pandemic planning.
Under the new plan, businesses pay a nominal annual fee to “reserve” their own stockpile of Tamiflu, which Roche will store and rotate to keep “in date.” The contract comes up for renewal annually, at which time companies will have the opportunity to re-evaluate their investment decision. If and when a company decides to take possession of the medicine-for example, if a novel strain of influenza virus begins human-to-human spread-they can purchase their dedicated product from Roche at the prevailing wholesale price. Roche will guarantee delivery within 48 hours in most circumstances.
Businesses can still purchase Tamiflu outright and consider predistribution to their employees, which is what some corporations have preferred.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
